281 473

Cited 0 times in

Cited 2 times in

A prognostic immune nutritional index can predict all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis

DC Field Value Language
dc.contributor.authorAhn, Sung Soo-
dc.contributor.authorPyo, Jung Yoon-
dc.contributor.authorSong, Jungsik Jason-
dc.contributor.authorPark, Yong Beom-
dc.contributor.authorLee, Sang Won-
dc.date.accessioned2023-08-09T07:04:05Z-
dc.date.available2023-08-09T07:04:05Z-
dc.date.created2023-11-02-
dc.date.issued2023-07-
dc.identifier.issn1759-720X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/196042-
dc.description.abstractBackground:Studies have proposed that nutritional and immune-related markers are relevant with patient outcomes of various medical conditions and could be a useful indicator of patient prognostication. Objectives:This study investigated whether a prognostic immune nutritional index (PINI) at diagnosis could predict adverse clinical outcomes in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Design:A retrospective, single-centre observational cohort analysis of patients with AAV. Methods:All-cause mortality and end-stage renal disease (ESRD) were investigated outcomes during the observation period. PINI was calculated by serum albumin (g/mL) x 0.9 - monocyte count (/mm(3)) x 0.0007, and the optimal cut-off of PINI was obtained using a Youden index-based bootstrapping method. Cox hazard analyses were performed to identify independent predictors of patient outcomes. Results:Of the 250 eligible patients, the median age of patients was 60.0 years, and 34.0% were men. During the disease course, 33 (13.2%) died and 42 (16.8%) developed ESRD, respectively. The ideal PINI cut-offs for all-cause mortality and ESRD were set as & LE;2.47 and & LE;3.12 (sensitivity and specificity of 75.1% and 60.6% for mortality and 46.2% and 78.6% for ESRD). AAV patients with PINI & LE;2.47 and those with PINI & LE;3.12 exhibited significantly higher rates for all-cause mortality and ESRD compared to those with PINI >2.47 and >3.12. In the multivariable Cox analysis, PINI & LE;2.47 (hazard ratio [HR]: 3.173, 95% confidence interval [CI]: 1.129, 8.916, p = 0.029) was independently associated with all-cause patient mortality; however, PINI & LE;3.12 was not independently associated with ESRD (HR: 1.097, 95% CI: 0.419, 2.870, p = 0.850). Conclusion:Findings from this study demonstrated PINI could predict all-cause patient mortality in AAV, and a higher clinical attention is warranted in those with PINI & LE;2.47 at initial diagnosis.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherSage Publications-
dc.relation.isPartOfTherapeutic Advances in Musculoskeletal Disease-
dc.relation.isPartOfTHERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleA prognostic immune nutritional index can predict all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorAhn, Sung Soo-
dc.contributor.googleauthorPyo, Jung Yoon-
dc.contributor.googleauthorSong, Jungsik Jason-
dc.contributor.googleauthorPark, Yong Beom-
dc.contributor.googleauthorLee, Sang Won-
dc.identifier.doi10.1177/1759720X231188818-
dc.relation.journalcodeJ03811-
dc.identifier.eissn1759-7218-
dc.identifier.pmid37529333-
dc.subject.keywordantineutrophil cytoplasmic antibody-
dc.subject.keywordend-stage renal disease-
dc.subject.keywordmortality-
dc.subject.keywordprognostic immune nutritional index-
dc.subject.keywordvasculitis-
dc.contributor.alternativeNamePark, Yong Beom-
dc.contributor.affiliatedAuthorAhn, Sung Soo-
dc.contributor.affiliatedAuthorPyo, Jung Yoon-
dc.contributor.affiliatedAuthorSong, Jungsik Jason-
dc.contributor.affiliatedAuthorPark, Yong Beom-
dc.contributor.affiliatedAuthorLee, Sang Won-
dc.identifier.scopusid2-s2.0-85166515794-
dc.identifier.wosid001036747800001-
dc.citation.volume15-
dc.citation.startPage1-
dc.citation.endPage12-
dc.identifier.bibliographicCitationTherapeutic Advances in Musculoskeletal Disease, Vol.15 : 1-12, 2023-07-
dc.identifier.rimsid81074-
dc.type.rimsART-
dc.description.journalClass1-
dc.description.journalClass1-
dc.subject.keywordAuthorantineutrophil cytoplasmic antibody-
dc.subject.keywordAuthorend-stage renal disease-
dc.subject.keywordAuthormortality-
dc.subject.keywordAuthorprognostic immune nutritional index-
dc.subject.keywordAuthorvasculitis-
dc.subject.keywordPlusINFLAMMATION-
dc.subject.keywordPlusHYPOALBUMINEMIA-
dc.type.docTypeArticle-
dc.description.isOpenAccessY-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalWebOfScienceCategoryRheumatology-
dc.relation.journalResearchAreaRheumatology-
dc.identifier.articleno1759720X231188818-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.